 NEW YORK, Aug. 12, 2020 GLOBE NEWSWIRE -- Eyenovia, Inc. NASDAQ: EYEN, a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print MAPTM therapeutics, today reported its financial results for the second quarter ended June 30, 2020. Second Quarter 2020 and Recent Business Highlights Announced exclusive license agreement with Arctic Vision Hong Kong Limited to develop and commercialize MicroPine and MicroLine in Greater China and South Korea; Resumed recruitment of Phase III CHAPERONE study for pediatric progressive myopia; and Preparing to submit the New Drug Application for MicroStat by the end of 2020.Earlier this week, we entered into a license agreement with Arctic Vision, a China-based ophthalmology company, to develop and commercialize MicroPine and MicroLine for the Greater China mainland China, Hong Kong, Macau and Taiwan and South Korean markets. This transaction, which includes payments of up to 45.75 million in potential license and product development fees as well as commercial supply terms or royalties, expands the commercial reach of our programs into markets where the number of myopic children is estimated at greater than 240 million, more than eight times that of the United States, commented Dr. Sean Ianchulev, Eyenovias Chief Executive Officer and Chief Medical Officer. In the coming months and subject to any impacts of COVID-19, we also look forward to initiating our Phase III VISION trials for MicroLine and plan to submit our New Drug Application for MicroStat to the FDA by the end of the year.Second Quarter 2020 Financial ReviewFor the second quarter of 2020, net loss was approximately 5.0 million, or 0.25 per share, compared to a net loss of approximately 5.3 million, or 0.44 per share for the second quarter of 2019.Research and development expenses totaled approximately 2.9 million for the second quarter of 2020, compared to approximately 3.6 million for the same period in 2019, a decrease of approximately 18.3.For the second quarter of 2020, general and administrative expenses were approximately 2.1 million compared to approximately 1.8 million for the second quarter of 2019, an increase of approximately 16.3.Total operating expenses for the second quarter of 2020 were approximately 5.0 million, compared to total operating expenses of approximately 5.4 million for the same period in 2019, a decrease of approximately 6.7. Operating expenses for the second quarter of 2020 include approximately 0.6 million of non-cash stock compensation expense.As of June 30, 2020, the Companys cash balance was approximately 10.2 million.Conference Call and WebcastThe conference call is scheduled to begin at 4:30pm ET on Wednesday, August 12, 2020. Participants should dial 1-866-916-2921 United States or 1-210-874-7771 International with the conference code 7380187. A live webcast of the conference call will also be available on the investor relations page of the Companys corporate website at the live webcast, the event will be archived on Eyenovias website for one year. In addition, a telephonic replay of the call will be available until August 19, 2020. The replay can be accessed by dialing 1-855-859-2056 United States or 1-404-537-3406 International with confirmation code 7380187.About Eyenovia Eyenovia, Inc. NASDAQ: EYEN is a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print MAPTM therapeutics. Eyenovias pipeline is currently focused on the late-stage development of microdosed medications for presbyopia, myopia progression and mydriasis. For more Information, please visit MicroPine for Progressive Myopia MicroPine atropine ophthalmic solution is for progressive myopia, a back-of-the-eye condition commonly known as nearsightedness. Progressive myopia is estimated to affect close to 5 million children in the United States who suffer from uncontrolled axial elongation of the sclera leading to increasing levels of myopia and in some cases major pathologic changes such as retinal atrophy, macular staphylomas, retinal detachment and visual impairment. MicroPine has been developed for comfort and ease-of-use in children. Microdose administration of MicroPine is anticipated to result in low systemic and ocular drug exposure. A recent therapeutic evidence assessment and review by the American Academy of Ophthalmology indicates Level 1 highest evidence of efficacy for the role of low dose atropine for progressive myopia Ophthalmology 2017;124:1857-1866; Ophthalmology 2016; 1232 391:399.Feasibility Dose-finding Atropine Studies: ATOM 1; ATOM 2; LAMP Independent Collaborative Group TrialsAbout MicroLine for Presbyopia MicroLine is a pharmacologic treatment for presbyopia. Presbyopia is the non-preventable, age related hardening of the lens, which causes a gradual loss of the eyes ability to focus on nearby objects and is estimated to affect nearly 113 million Americans. Current treatment options are typically device-based, such as reading glasses and contact lenses. Pilocarpine ophthalmic solution is known to constrict the pupil and improve near-distance vision by creating an extended depth of focus through its small aperture effect. Eyenovia believes that its administration of pilocarpine using the companys high precision microdosing technology could provide a meaningful improvement in near vision while enhancing tolerability and usability.About MicroStat for Mydriasis MicroStat is Eyenovias first-in-class fixed-combination micro-formulation product tropicamide 1 - phenylephrine 2.5 candidate for pharmacologic mydriasis eye dilation, which is targeted to improve the efficiency of the estimated 80 million office-based comprehensive and diabetic eye exams performed every year in the United States, as well as the estimated 4 million pharmacologic mydriasis applications for cataract surgery. Developed for use without anesthetic, we are developing MicroStat to improve the efficacy and tolerability of pharmacologic mydriasis.About Optejet and MicroRx Ocular Therapeutics Eyenovias Optejet microdose formulation and delivery platform for ocular therapeutics uses high-precision piezo-print technology to deliver 6-8 μL of drug, consistent with the capacity of the tear film of the eye. We believe the volume of ophthalmic solution administered with the Optejet is less than 75 of that delivered using conventional eyedroppers, thus reducing overdosing and exposure to drug and preservatives. Eyenovias patented microfluidic ejection technology is designed for fast and gentle ocular surface delivery, where solution is dispensed to the ocular surface in approximately 80 milliseconds, beating the ocular blink reflex. Successful use of the Optejet has been demonstrated more than 85 of the time after basic training in a variety of clinical settings compared to 40 50 with conventional eyedroppers. Additionally, its smart electronics and mobile e-health technology are designed to track and enhance patient compliance.Forward Looking Statements Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions, including estimated market opportunities for our product candidates. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors discussed from time to time in documents which we file with the SEC. In addition, such statements could be affected by risks and uncertainties related to, among other things: impacts of and uncertainty related to COVID-19; fluctuations in our financial results, particularly given market conditions and the potential economic impact of COVID-19; our need to raise additional money to fund our operations for at least the next 12 months as a going concern; our ability to timely develop, implement and maintain manufacturing, commercialization and marketing capabilities and strategies for our product candidates; risks of our clinical trials, including, but not limited to, the costs, design, initiation and enrollment which could still be adversely impacted by COVID-19 and resulting social distancing, timing, progress and results of such trials; the potential impacts of COVID-19 on our supply chain; the timing and our ability to submit applications for, obtain and maintain regulatory approvals for our product candidates; our estimates regarding the potential market opportunity for our product candidates; the potential advantages of our product candidates; the rate and degree of market acceptance and clinical utility of our product candidates; the potential success of our reprioritized pipeline; any cost savings related to our reprioritized pipeline; our ability to attract and retain key personnel; intellectual property risks; changes in legal, regulatory and legislative environments in the markets in which we operate and the impact of these changes on our ability to obtain regulatory approval for our products; and our competitive position. 